Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers 论文

2013Nature引用 320
DOI
Melanoma and MAPK PathwaysProtein Tyrosine PhosphatasesComputational Drug Discovery Methods
Computational Drug Discovery MethodsMelanoma and MAPK PathwaysProtein Tyrosine Phosphatases
相关技术:Computational Drug Discovery Methods
关系图谱

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers · 作者

M

Marcia Belvin

S

Shiva Malek

L

Lori S. Friedman

M

Mark Ultsch

C

Christian Wiesmann

M

Mary J. C. Ludlam

D

Daniel J. Anderson

S

Shiuh-Ming Luoh

J

Jocelyn Chan

K

Klaus P. Hoeflich

M

Mark Merchant

C

Christine Orr

A

Ariana Peck

M

Mark Zak

J

Joanne F. M. Hewitt

R

Robert A. Heald

S

Steve Price

K

Kyung Song

H

Huifen Chen

J

Jacob R. Haling

G

Georgia Hatzivassiliou